+1 877 705 191424 / 7
HIPAA Compliant
ISO 27001 Certified

Completed

Phase 4
Age: 30Years - 55Years
All Genders
ID00000438

Naltrexone Treatment for Alcoholism Predicting Outcome

Led by Johns Hopkins University · Updated on 2010-05-14

192

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

This study will evaluate the effectiveness of the medication naltrexone (Revia) for treating alcoholism. Individuals will be inpatients for a 2 week period and provide assessments of their alcohol withdrawal symptoms, craving, and mood. Following hospital discharge, individuals will be assigned randomly to receive naltrexone daily, naltrexone twice a day or a placebo. This part of the study will last 12 weeks, with regular measurements of drinking level, craving and mood. Assessments will be conducted 6 and 12 months after the beginning of the study.

CONDITIONS

Brief Title

Naltrexone Treatment for Alcoholism

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here